By Gnaneshwar Rajan and Sriparna Roy Jan 30 (Reuters) - Regeneron Pharmaceuticals' executives voiced confidence in its ...

The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) today announced the ...

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...

In an era where AI-driven drug discovery accelerates candidate generation faster than traditional systems can evaluate them, ...

A large share of medicines developed today may never reach patients for a surprisingly simple reason: they cannot dissolve well enough in water. For most treatments, the oral route remains the gold ...

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...

Explore groundbreaking research on pancreatic cancer treatment that shows promise in inducing complete tumour regression.

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical ...

Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...